Stock LUN LUNDBECK
Add to a list
To use this feature you must be a member
Log inSign up

Lundbeck Share Price Nasdaq Copenhagen

Equities

LUN

DK0061804697

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 08:29:47 21/05/2024 pm IST 		5-day change 1st Jan Change
32.7 DKK +0.93% Intraday chart for Lundbeck +9.83% -5.33%
15/05 H LUNDBECK : Q1 beat adds momentum to the recent share price rally Alphavalue
15/05 Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 21.09B 3.07B 255B Sales 2025 * 22.13B 3.22B 268B Capitalization 36.11B 5.25B 437B
Net income 2024 * 3.08B 447M 37.23B Net income 2025 * 3.46B 503M 41.85B EV / Sales 2024 * 1.5 x
Net cash position 2024 * 4.47B 650M 54.12B Net cash position 2025 * 8.04B 1.17B 97.39B EV / Sales 2025 * 1.27 x
P/E ratio 2024 *
12.2 x
P/E ratio 2025 *
10.5 x
Employees 5,681
Yield 2024 *
2.39%
Yield 2025 *
2.75%
Free-Float 30.74%
More Fundamentals * Assessed data

Chart Lundbeck

Dynamic Chart

Latest news about Lundbeck

H LUNDBECK : Q1 beat adds momentum to the recent share price rally Alphavalue
Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024 CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period Alphavalue
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024 CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia CI
H. Lundbeck A/S Announces Management Appointments CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023 CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug MT
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage CI
More news

Latest transcript on Lundbeck

Logo Lundbeck
H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024
More transcripts

Analyst Recommendations on Lundbeck

H LUNDBECK : Q1 beat adds momentum to the recent share price rally Alphavalue
H LUNDBECK : Lundbeck is well-poised to sail through the transition period Alphavalue
More recommendations

Press releases Lundbeck

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024 AQ
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck AQ
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD AQ
Lundbeck : Articles of Association PU
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia AQ
More press releases

Quotes and Performance

1 day+0.69%
Current month-5.33%
Current year-5.33%
More quotes

Highs and lows

3 years
28.52
Extreme 28.52
41.46
5 years
28.52
Extreme 28.52
61.70
10 years
22.30
Extreme 22.3
95.54
More quotes

Quotes

Date Price Change Volume
21/24/21 32.7 +0.93% 62 181
17/24/17 32.4 +0.15% 128,109
16/24/16 32.35 -0.46% 270,280
15/24/15 32.5 +7.26% 586,907
14/24/14 30.3 +0.17% 150,077

Delayed Quote Nasdaq Copenhagen, May 21, 2024 at 08:29 pm IST

More quotes

Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
Pharmaceuticals
Calendar
21/08/2024 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Lundbeck

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37.4 DKK
Average target price
39.96 DKK
Spread / Average Target
+6.84%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+19.34% 73.31B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-4.85% 23.98B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+4.89% 8.8B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+9.21% 8.6B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.79% 8.07B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.41% 4.16B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+12.27% 4.14B
GALENICA AG Stock Galenica AG
-2.75% 3.88B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+23.24% 3.72B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. LUN Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW